The Pharmacy and Poisons Board has approved the use of a prescription drug for the treatment of prostate cancer.
The drug, ZYTIGA (abiraterone acetate), is manufactured by Janssen, one of the pharmaceutical companies of Johnson & Johnson.
The local pharmacy regulator has approved the use of the once-daily medication for the treatment of metastatic castration-resistant prostate cancer ahead of a chemotherapy regime.
“The drug is only licensed for the treatment of advanced prostate cancer cases post-chemotherapy,” Janssen Kenya Country Manager Marseille Onyango said.
Trade between African and GCC countries stands at $ 121 billion in 2023, double of what it was in 2016.…
Family members struggling after one week after of Cyclone Chido ripped through the French island territory of Mayotte expressed helplessness…
The United Arab Emirates has launched its orphanage project in Ethiopia's Oromia region on the orders of President Sheikh Mohamed…
In just four months, 100 women have been killed, the majority by males they knew including spouses. Prime Cabinet Secretary…
The Ghanaian entertainment industry is in deep mourning following the sudden death of Bright Owusu, better known as C Confion.…
Since the beginning of December more than five hundred people have lost their lives on the nation's highways. Barbara Creecy,…
This website uses cookies.